IL1B and chronic kidney disease: Similarly, the CANTOS trial and related studies using IL‐1β monoclonal antibodies demonstrated that targeting chronic inflammation reduced cardiovascular risk, particularly in CKD patients, although at the cost of increased infection‐related mortality [72, 73].